284 related articles for article (PubMed ID: 12085990)
21. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells.
Fan X; Roy E; Zhu L; Murphy TC; Ackert-Bicknell C; Hart CM; Rosen C; Nanes MS; Rubin J
Endocrinology; 2004 Feb; 145(2):751-9. PubMed ID: 14563699
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
Viereck V; Emons G; Lauck V; Frosch KH; Blaschke S; Gründker C; Hofbauer LC
Biochem Biophys Res Commun; 2002 Mar; 291(3):680-6. PubMed ID: 11855844
[TBL] [Abstract][Full Text] [Related]
23. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
24. Influence of baicalin on the expression of receptor activator of nuclear factor-kappaB ligand in cultured human periodontal ligament cells.
Wang GF; Wu ZF; Wan L; Wang QT; Chen FM
Pharmacology; 2006; 77(2):71-7. PubMed ID: 16636611
[TBL] [Abstract][Full Text] [Related]
25. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
[TBL] [Abstract][Full Text] [Related]
26. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
27. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
28. PTH differentially regulates expression of RANKL and OPG.
Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
[TBL] [Abstract][Full Text] [Related]
29. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.
Rubin J; Ackert-Bicknell CL; Zhu L; Fan X; Murphy TC; Nanes MS; Marcus R; Holloway L; Beamer WG; Rosen CJ
J Clin Endocrinol Metab; 2002 Sep; 87(9):4273-9. PubMed ID: 12213884
[TBL] [Abstract][Full Text] [Related]
30. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
31. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.
Thomas GP; Baker SU; Eisman JA; Gardiner EM
J Endocrinol; 2001 Aug; 170(2):451-60. PubMed ID: 11479141
[TBL] [Abstract][Full Text] [Related]
32. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
[TBL] [Abstract][Full Text] [Related]
33. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
[TBL] [Abstract][Full Text] [Related]
34. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
35. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
36. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
[TBL] [Abstract][Full Text] [Related]
37. Dental cells express factors that regulate bone resorption.
Rani CS; MacDougall M
Mol Cell Biol Res Commun; 2000 Mar; 3(3):145-52. PubMed ID: 10860862
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
39. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
40. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells.
Chen Q; Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2004 Oct; 36(10):674-8. PubMed ID: 15523591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
